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doi:10.1016/j.jtcvs.2006.09.119he natural mitral valve is a complex and finely tuned structure, very well
suited to its purpose. It has the unusual feature of having fingerprint anatomic
variation from heart to heart and yet the correct essentials for optimal
unction in each heart. Among the many features is that the mural annulus expands
or flow and narrows for closure and that the multiscalloped posterior leaflet makes
xpansion and contraction possible. In diastole the scallops are separate; in systole
hey are compressed into a shelf.
The chordae are of two types, despite their extreme variability: one to align the
ree edges and one to bear the load of the closed valve and transmit that load to the
entricular wall and aid in systolic ejection.
The Encyclopedia Britannica of 1895 described all of the devices for allowing
uid to travel in one direction and preventing it from traveling in an opposite
irection that had been developed by the engineers of the Industrial Revolution. The
rinciple of every type of mechanical valve that we have adapted for use in the
eart in the last 45 years is to be found there. There are even flap valves made of
eather. There is no valve with a dynamic orifice that enlarges for flow and narrows
or closure. There is no valve with downstream support divided between one set of
hordae to align the leaflet edges and one set to support the load of the closed valve.
here is no valve that resembles the natural mitral valve.
Surgeons started trying to design artificial mitral valves in the late 1950s. Most
ought mechanical solutions. If we define success as replacement of the mitral valve
ollowed by discharge of a live patient from the hospital, then the first success
ollowed the implantation of a stentless mitral valve made by Nina Braunwald and
nserted by Glen Morrow in 1960. It was a bileaflet valve of molded polyurethane
ith its free edges supported by polyester chordae brought together into two groups
nd secured outside the ventricular wall. It resembled a rheumatic valve after a good
ommissurotomy. Ever since then the dream of a stentless chordally supported
itral valve has persisted.
Stentless mitral valves all have a more or less bileaflet structure with a pliable
ewing ring and a distal connection between the leaflet edges and the left ventricular
all. They can be classified into three main types:
1. Harvested natural mitral valves that may be allograft or xenograft.
2. Tubular sleeves of biological tissue that are directly attached at each side to
the left and right papillary muscles.
3. More or less bileaflet valves with synthetic sutures or extensions of the leaflet
edges that are attached to papillary muscles to maintain annular–papillary
connection.
I have excluded for brevity’s sake autograft or allograft harvested pulmonary or
ortic valves mounted upside down in a tube graft. Although these valves have been
alled “stentless,” the tube controls their motion very much the way a 3-pronged
tent does.
arvested Natural Mitral Valves
t is fair to say that there has never been widespread use of these devices despite
esearch that began in the late 1960s. The major reason for this has been the extreme
natomic irregularity of papillary muscles and their chordal origins. This irregularity
pplies, naturally, to both donor and host, so that there needs to be selection of a
onor and, to a lesser extent, a host with properly matching anatomy. Homograft
nsertion was greatly helped by the technique of side-by-side papillary attachment
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Lombined with the routine use of an annuloplasty ring.
car1 developed these improvements, but as the leading
xponent of homograft mitral valve replacement he ac-
nowledges that its use is still in the research stage.
In the case of xenografts, attempts were made to simplify
he fixing of the valve to the papillary muscle by suturing
he left and right donor papillary/chordal complexes to a
ericardial flap2 or enclosing them in a tube,3 but in neither
ase was the expected benefit achieved. Both homografts
subject to strength deterioration between harvesting and
se) and aldehyde-fixed xenografts have had early chordal
upture and leaflet tears in clinical use.
If we imagine the embryonic chordae developing exactly
he right thickness, strength, and length for the function they
re performing in the growing heart, it can be understood
hat a tilting of the attachment could subject chordae to
tresses greater than those they grew to tolerate. Apart from
he one xenograft porcine mitral valve that did reach clinical
se for a limited time,2 there have been several versions that
id not get past the animal testing stage.
ubular Sleeves of Biological Tissue
ubular sleeves have been made of untreated and aldehyde-
anned autogenous pericardium, as well as aldehyde-tanned
enograft pericardium.4-6 In most, the anterior part of the
ube is deeper than the posterior so the closure line has a
urve that is somewhat parallel to the mural annulus. Ven-
ricular attachment has generally been to the inside of each
apillary muscle at the commissures between the deeper
nterior leaflet and the shallower posterior leaflet. At least
ne design has extra layers of material for reinforcement of
he attachment. In my experience of copying and testing
alves of this type in vitro and in vivo, and in my observa-
ions of the designs of others implanted in animals and
umans, I have observed that the pericardium representing
he posterior leaflet commonly develops folds in closure.5
hese folds give the appearance of multiple scallops. With
contractile annulus and a supple sewing “ring,” nature
eproduces in closure the natural scalloped form of the
ative mitral valve. Deac and colleagues,6 who worked long
nd hard to promote the concept of stentless mitral valves,
ublished acceptable results of a small series of homemade
ersions of this category of valve, but despite much effort at
ommercialization this has not been achieved.
ileaflet Valves With Chordal Support
an der Spuy7 described such a valve made from fascia lata
nd polyester chordae. The valve described in this issue of
he Journal by Jose Navier and coauthors8 and the Quattro
alve9 are two valves with this form in which the chordal
upport is provided by extensions of the leaflet pericardium.
oth have resemblances to the natural valve, having a large
nterior leaflet meeting a shallow posterior leaflet. The s
62 The Journal of Thoracic and Cardiovascular Surgery ● Apriormer has a shelf-like posterior leaflet that resembles the
helf-like form of the posterior leaflet of the natural valve
fter the scallops have been compressed together by normal
ystolic annular contraction or fused at their commissures
y the rheumatic process. In the Quattro valve there are
hree distinct posterior scallops connected at the commis-
ures. The left and right chordal extensions of the leaflets in
oth these designs are sutured to the bulky anterior part of
ach papillary muscle. In closure the three posterior scallops
f the Quattro valve meet along their sides, producing an
ppearance similar to the closed natural valve. Both these
alves are constructed from aldehyde-tanned xenograft peri-
ardium. The Quattro valve has an anticalcification post-
anning treatment. There have been multiple publications on
he Quattro valve describing various aspects of its perfor-
ance, the most recent being a report of experience between
996 and 2004 from the three sites where the majority of the
rial implants were performed.9
artial Replacement
avia and colleagues8 included the concept of partial re-
lacement. This was tried extensively in the early days of
itral valve repair, using pericardium for selective leaflet
nd chordal replacement.10
The method described by Navia and colleagues8 involves
ncising the continuous sleeve of natural leaflet tissue cir-
umferentially so it is no longer connected with the annulus.
ontinuity is restored by suturing the bileaflet valve without
ts chordal parts to the proximal and distal margins of the
ut leaflet tissue. There was once a rheumatic pathology in
hich the leaflets shrunk but both leaflet tissue and chordae
etained some flexibility. One remedy was to restore the
engths of the shortened leaflets with separate gussets of
ericardium.11 Another remedy, described by Bailey and
irose12 and Edwards and Holdefer,13 using untreated au-
ogenous pericardium, was essentially the same as Navia
nd colleagues’ method.8 Navia and colleagues’ use of part
f this prosthesis will certainly work for the pathology
escribed, but the indication for it will be uncommon.
The questions that inevitably arise from all this work are
1) What has been learned? and (2) Where are we going?
hat Has Been Learned?
mplantability
he need to attach the valve to the papillary muscles un-
uestionably makes these valves more difficult to insert. In
he Quattro trial a majority of the surgeons who were asked
nd agreed to participate seemed to manage the insertion
ell, but they were experts at exposing the mitral valve. I
uspect the sleeve-type valves may be the easiest.
emodynamics
t is tempting to assume that, like stentless aortic valves,
tentless mitral valves have as their raison d’etre better
l 2007
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Lemodynamics when annuli are small. This is not so: In
dults it is rare for the annulus to be so small as to force the
nsertion of a mitral valve too small to produce the imme-
iate improvement in hemodynamics and symptoms that is
he universal response after mitral valve replacement. Even
he possibility that resolution of pulmonary hypertension
ay depend on a specific mitral effective orifice index is
roving difficult to establish. There is a simple relationship
etween the pressure needed to drive a normal stroke vol-
me across the orifice of an aortic valve that determines
hether the resulting decrease in left ventricular pressure
ill allow hypertrophy to resolve. The mechanisms that
ause pulmonary hypertension and allow it to resolve are far
ore complex, and in some patients, despite excellent relief
f mitral obstruction, pulmonary hypertension persists for
s long as 1 year.
In general, stentless valves have hemodynamic perfor-
ance that is equivalent to the general run of current mitral
rostheses. Of the three categories in our classification the
leeve valves have larger orifice areas for a given mounting
ize. This may be related to the absence of subvalvular
pparatus in the flow path. Stentless valves are susceptible
o oversizing, which results in crowding of folded leaflet
issue in the orifice. Their flexible sewing rings also make
hem susceptible to distortion, which can result in insuffi-
iency. In all of these valves the sewing rings do not and
annot expand for diastolic flow.
urability
urability of a tissue valve results from resistance to struc-
ural failure in response to repetitive cycling and resistance
o calcification over time, particularly in young patients.
annus formation is generally regarded as nonstructural
ailure, especially when evaluating mechanical valves; in
tentless valves it can have the effect of fundamentally
nterfering with function.
All stentless valves that have undergone long-term ani-
al or human trials have had structural failure in the form
f tears. These have occurred early in harvested valves and
fter some years in the others. In the case of the Quattro, the
esign called for a partial imitation of nature with selection
f pericardium with the collagen fiber direction running
etween the annulus and the papillary attachment in the
eaflet/chordal flap combinations. In multiple wear tests,
omplete resistance to tears was demonstrated. However, in
he clinical trial 3 cases developed tears after 4 to 5 years,
ecessitating reoperation. Examination of the removed
alves indicated that the collagen fibers ran in a transverse
irection parallel with the tears: The system for identifying
ber direction was not sufficiently robust and had to be
hanged.
The pericardium used in the construction of the Quattro
alve has an anticalcification treatment. It was hoped that
urability would be enhanced by the absence of stent- M
The Journal of Thoracicroduced stresses, which in 3 leaflet bioprostheses are re-
ated to the location of both calcium deposits and tears. The
uattro trial was unique in the deliberate choice of young
atients to test the effectiveness of the treatment. The trial
howed a much later onset of calcification in patients aged
ess than 40 years than was seen in stented, untreated
ioprostheses in the past, but from 6.5 years on some
alcification has been seen. Pannus has also occurred, and as
he fibrous tissue starts growing onto the leaflets it affects
exibility, and therefore function, immediately. In all cases
n which valves have been removed, the healing to the
nnulus has been sufficiently fibrous to suggest that free
nnular contraction may be limited.
entricular Function
entricular function was well preserved in the Quattro
ases. The attachment of free edge chordal support to the part
f the papillary muscles normally supporting the anterior leaf-
et achieved this without the need for separate second-order
hordae. The automatic maintenance of annular–papillary con-
inuity is the feature common to all stentless mitral valves.
hat Has Been Achieved and Where Are We
oing?
here were two dreams in the beginning. The first was to
ecreate the natural valve. It is clear that apart from the fact
hat the artificial valves we have made are not alive and
enerally are a form of leather, the best we achieve resembles
valve with mild rheumatic disease and a fixed annulus.
The second dream was to create a durable biological
alve for the special needs of the developing world. It is no
oincidence that virtually all the innovators have had per-
onal experience of those needs. We have made some
rogress, but to prove a substantial improvement will take
onger follow-up of young patients. It will not be sufficient
o aim at the statutory 800 patient-years for a single-site
evice. This is commonly done with a large number of
atients followed for a short time. It can be done with 400
atients followed for 2 years. Despite the expense of this,
he fact that it can be done relatively quickly is vital to
tockholder companies beholden to the need to satisfy Wall
treet analysts. But 800 patient-years garnered in this way is
otally useless to determine resistance to calcification; for
hat, a follow-up of 80 young patients, each followed for at
east 10 years, is far more likely to provide the answer. To
ait 10 years to be able to sell a product at low-profit
argins is not attractive to investors.
North America and Europe, with a pocket in Japan, have
een the markets to which major valve companies are
imed. With the growth of large middle classes in China and
ndia, valves developed in North America and Europe are
ncreasingly being sold there at the relatively high prices
hat make it possible to make a profit on devices developed
o the standards of the Association for the Advancement ofedical Instrumentation, Food and Drug Administration,
and Cardiovascular Surgery ● Volume 133, Number 4 863
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Lnd International Organization for Standardization. The ru-
al poor in the developing world continue to contract rheu-
atic heart disease and to need a durable inexpensive de-
ice that does not require anticoagulation.
For the dreamers, the road ahead is very hard. The
aradigm of valve development in the developed world does
ot work for them. It is perhaps a moot point whether
heumatic fever will be eradicated before a cheap and du-
able device without requirement for anticoagulation is fi-
ally proven. I suspect that there will still be a reservoir of
atients needing the latter before the former is achieved.
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Results of ACOSOG Z0050 trial: The utility of FDG-PET in staging potentially operable
non–small cell lung cancer
To the Editor:
As the result of re-review of data from the American College of Surgeons Oncology Group Z0050
trial1 in preparation for an analysis of the use of brain FDG-PET in operable lung cancer, 2 some
corrections to the originally published data are reported. As published, FDG-PET correctly identified
M1 disease in 15 of 287 patients (5.2%). It was reported that in 19 of 287 evaluable patients (6.6%)
possible M1 disease was ruled out with confirmatory procedures (additional imaging or biopsy).
Re-review of the PET reports in this group revealed that two cases (1 brain, 1 bone) were erroneously
included by only blinded PET review and 4 cases (3 brain, 1 esophagus) were not suspicious per site
PET report re-read. It was also reported that M1 disease was indicated by PET in 8 additional patients
that the surgeon chose to overrule. Re-review shows that two cases (1 brain, 1 esophagus) were
erroneously included.
These corrections do not alter the conclusions of the ACOSOG Z0050 trial. However, the reported
percentage of patients with PET findings indicative of M1 disease subsequently proven not to be
metastatic decreases from 6.6% to 4.5%.
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